Trial · NCT06319846
Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）
NCT06319846, Phase 3, Recruiting, Beijing Tiantan Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）. Trials, record NCT06319846. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06319846
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）
- NCT number
- NCT06319846
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 4,674 participants, estimated
- Lead sponsor
- Beijing Tiantan Hospital
- Conditions
- Ischemic Stroke, Acute, TIA, Symptomatic Intracranial Artery Stenosis
- Interventions
- Tirofiban, Placebo
- First posted
- 2024-03-20
- Last updated
- 2024-07-12
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Any new ischemic stroke at 3-month | at 3-month | Incidence of any new ischemic stroke at 3-month |
| Primary | Type 3 or 5 bleeding events according to the BARC criteria at 3-month | at 3-month | Incidence of type 3 or 5 bleeding events according to the BARC criteria at 3-month |
| Secondary | Any new ischemic stroke within 1 year | within 1 year | Incidence of any new ischemic stroke within 1 year |
| Secondary | New clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ myocardial infarction/vascular death) within 3 months and 1 year; Each new vascular event will be independently evaluated. | Within 3 months after randomization and 1 year | Incidence of new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ myocardial infarction/vascular death) within 3 months and 1 year; Each new vascular event will be independently evaluated. |
| Secondary | Disabling stroke (Modified Rankin Scale score, mRS>1) at 3 months and 1 year | at 3 months and 1 year | Proportion of patients with disabling stroke (Modified Rankin Scale score, mRS\>1) at 3 months and 1 year. Scores on the modified Rankin scale range from 0 (no neurologic deficit) to 6 (death). |
| Secondary | Incidence and severity of recurrent stroke and TIA | Within 3 months after randomization and 1 year | Incidence and severity of recurrent stroke and TIA during follow-up to 3 months and 1-year (Severity is measured using a six-level ordered categorical scale that incorporates the mRS: fatal stroke/severe non-fatal stroke \[mRS 4 or 5\]/moderate stroke \[mRS 2 or 3\]/mild stroke \[mRS 0 or 1\]/TIA/no stroke-TIA) |
| Secondary | Neurological impairment at 3 months (NIHSS increased≥4 from baseline ). | at 3 months | Proportion of patients with neurological impairment at 3 months ( National Institutes of Health Stroke Scale \[NIHSS\] score increased≥4 from baseline). |
| Other | Type 3 or 5 bleeding events (BARC definition) at 1 year | at 1 year | Proportion of patients with type 3 or 5 bleeding events (BARC definition) at 1 year. |
| Other | Type 2, 3 or 5 bleeding events according to the BARC criteria at 3-month and 1-year. | at 3-month and 1-year | Proportion of patients with type 2, 3 or 5 bleeding events according to the BARC criteria at 3-month and 1-year. |
| Other | All bleeding events (type 1-5 bleeding events according to the BARC criteria) | at 3-month and 1-year | All bleeding events (type 1-5 bleeding events according to the BARC criteria) at 3-month and 1-year; Each bleeding event will be independently evaluated |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06319846
GET https://conductscience.org/api/trials/v1/NCT06319846/registered